| Literature DB >> 25026206 |
Taru Muranen1, Funda Meric-Bernstam2, Gordon B Mills3.
Abstract
In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.Entities:
Mesh：
Substances：
Year: 2014 PMID： 25026206 DOI： 10.1016/j.ccr.2014.06.020
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743